BioCentury
ARTICLE | Emerging Company Profile

Versant’s Cimeio debuts with $50M to shield cell therapies with gene editing

Start-up based in Basel, Boston reaches for new cell therapy and transplant applications with cell shielding technology

April 13, 2022 12:35 PM UTC

As the latest company to emerge from Versant, Cimeio has a new approach to hematopoietic stem cell transplants that could both reduce the burden of conditioning regimens and address residual disease ...





Complimentary access available. Register for a free account.

Already have an account? Log in

BCIQ Company Profiles

Versant Ventures